Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

35.99 -0.24 (-0.66%)

Streaming Delayed Price Updated: 12:57 PM EST, Feb 24, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	303,735
Open	36.50
Bid (Size)	35.91 (200)
Ask (Size)	36.06 (100)
Prev. Close	36.23
Today's Range	35.64 - 37.05
52wk Range	5.350 - 38.69
Shares Outstanding	44,188,534
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Performance

YTD	+16.5%	+16.5%
1 Month	+23.0%	+23.0%
3 Month	+18.6%	+18.6%
6 Month	+90.7%	+90.7%
1 Year	+323.4%	+323.4%

More News

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

Via The Motley Fool

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Via The Motley Fool

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Via The Motley Fool

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 18, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

February 11, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 16, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Top movers in Monday's pre-market session ↗

January 12, 2026

Via Chartmill

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

January 11, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 16, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗

December 10, 2025

Via The Motley Fool

Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗

December 09, 2025

Via Chartmill

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

December 01, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

November 18, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

November 17, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

November 05, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

6 Analysts Have This To Say About Stoke Therapeutics ↗

November 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 04, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Stoke Therapeutics, Inc. - Common Stock publicly traded?

Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?

Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?

The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market

What is the current price of Stoke Therapeutics, Inc. - Common Stock?

The current price of Stoke Therapeutics, Inc. - Common Stock is 35.99

When was Stoke Therapeutics, Inc. - Common Stock last traded?

The last trade of Stoke Therapeutics, Inc. - Common Stock was at 02/24/26 12:57 PM ET

What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?

The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.59B

How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?

Stoke Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.